Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | APAF1 | O14727 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyanide SCHEMBL25406275 | 0.82 | GAA (0.44) | ALDH1A1LMNA | |
| Cyanide SCHEMBL25407117 | 0.73 | — | — | |
| SCHEMBL30349861 | 0.72 | PARP1 (0.47) | ALDH1A1KDM4ESMN1; SMN2 | |
| Cyanide SCHEMBL25404739 | 0.72 | MEN1 (0.33) | ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL18378752 | 0.70 | CYP1A2 (0.46) | ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL18368383 | 0.69 | TSHR (0.36) | ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL18379277 | 0.68 | TDP1 (0.39) | ALDH1A1SMN1; SMN2 | |
| Cyanide SCHEMBL25406727 | 0.68 | PARP1 (0.51) | ALDH1A1LMNAKDM4E | |
| SCHEMBL30349956 | 0.65 | GAA (0.66) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL26279754 | 0.64 | P2RX7 (0.42) | ALDH1A1KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295095-A1 | NOVEL FUSED-HETEROCYCLYL-CARBONOHYDRAZONOYL DICYANIDE COMPOUNDS AND USE THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2023-09-21 | — | — | US | claimed |
| EP-4169905-A1 | NOVEL FUSED HETEROCYCLIC CARBONOHYDRAZONOYL DICYANIDE COMPOUND AND USE THEREOF | Korea Institute of Science and Technology (KR) | 2023-04-26 | — | — | EP | claimed |
| US-20230295095-A1 | NOVEL FUSED-HETEROCYCLYL-CARBONOHYDRAZONOYL DICYANIDE COMPOUNDS AND USE THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2023-09-21 | — | — | US | disclosed |
| EP-4169905-A1 | NOVEL FUSED HETEROCYCLIC CARBONOHYDRAZONOYL DICYANIDE COMPOUND AND USE THEREOF | Korea Institute of Science and Technology (KR) | 2023-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295095-A1 | NOVEL FUSED-HETEROCYCLYL-CARBONOHYDRAZONOYL DICYANIDE COMPOUNDS AND USE THEREOF | CBR3, DBF4, DDT | ALDH1A1 1343/4885F2 1522/4885LMNA 1471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.